Status:
TERMINATED
The Role of Serotonin in Seizures
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Epilepsy
Seizures
Eligibility:
All Genders
18-60 years
Brief Summary
This study will investigate the role that a brain chemical called serotonin plays in seizures. Serotonin, present naturally in the brain, helps transmit signals between nerve cells. Glucose is a sugar...
Detailed Description
Objective: To study serotonergic transmission in epilepsy and its relation to cerebral glucose metabolism, mesial temporal sclerosis, and depression. Study population: Patients with localization-rela...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients must have seizures documented by appropriate clinical and laboratory studies . This criterion will be established by studies performed by the referring physicians, preliminary screening in the NINDS Clinical Epilepsy Section outpatient clinic, or if necessary, inpatient video-EEG monitoring.
- Male and Female subjects aged between 18 and 60 years
- Healthy control subjects will also be recruited.
- Subjects must be able to give written informed consent prior to participation in this study.
- EXCLUSION CRITERIA:
- Patients younger than 18 or older than 60 years old. There is evidence for reduced 5HT1A receptor binding in patients over 60.
- Patients with a known treatable seizure etiology such as neoplastic or infectious disease.
- Patients with MRI findings consistent with brain tumors, trauma or AVMs.
- Patients with progressive neurologic disorders.
- Patients with a history of significant medical disorders, or requiring treatment with drugs
- that can not be stopped, and would interfere with the study, except for antidepressants.
- Patients with cancer.
- Patients not capable of giving an informed consent.
- Patients who had seizure activity 24 hours prior to the study.
- Women who are pregnant or nursing
- Subjects who are current smokers, and cannot stop for at least two weeks before the PET scan, as smoking may affect serotonergic neurotransmission.
- Healthy subjects must be free from a personal history of seizure disorders
- Patients with coagulation abnormalities.
Exclusion
Key Trial Info
Start Date :
February 20 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2015
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00439387
Start Date
February 20 2007
End Date
June 5 2015
Last Update
July 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892